About: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.60 (-6.01%)
ACRS NASDAQ Aclaris Therapeutics Inc
Aclaris Therapeutics Inc share price
ACRS price activity
Last Price
$3.600
Change (24hr)
-0.23 USD (-6.01%)
Volume
3.43M
Volume (4w avg)
-
Open
$3.80
Day Range
$3.60 - $3.80
Previous Close
$3.83
Last Trade
12 Oct, 8:27 pm GMT+0
Delayed
12 Oct, 8:27 pm GMT+0
ACRS price performance
Delayed
12 Oct, 8:27 pm GMT+0
ACRS Market Signals